Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
← catalyst calendarNCT04794699 · readout in 141 d
Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
169actual
Sites
37
Countries
Australia, France, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-14 | actual | When the study began enrolling |
| Primary completion | 2027-01-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-04 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Interventions
- Drug: IDE397
- Drug: Sacituzumab govitecan
Primary outcomes
what the primary-completion date above is the date OFDose-limiting Toxicities (DLTs) of IDE397
measured 21 days following the first dose of IDE397
Dose-limiting Toxicities (DLTs) of IDE397 in combination with sacituzumab govitecan
measured 21 - 28 days following the first dose of IDE397
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397
measured Approximately 2 years
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of IDE397 in combination with sacituzumab govitecan
measured Approximately 2 years
To evaluate preliminary anti-tumor activity of IDE397 as monotherapy and in combination with sacituzumab govitecan-hziy in expansion arms
measured Approximately 2 years
Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed